Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.56 |
| ▸ | REN | P00797 | 8/20 | 0.51 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.48 |
| ▸ | GRPR | P30550 | 1/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.44 |
| ▸ | NPY1R | P25929 | 3/20 | 0.44 |
| ▸ | NPY4R | P50391 | 3/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | NPY2R | P49146 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18862078 | 0.85 | SLC15A2 (0.56) | SLC15A2REN | |
| SCHEMBL19051545 | 0.84 | SLC15A2 (0.53) | SLC15A2RENSLC6A5HRH1 | |
| SCHEMBL15185869 | 0.84 | SLC15A2 (0.56) | SLC15A2RENSLC6A5GRPR | |
| SCHEMBL19051548 | 0.84 | REN (0.57) | SLC15A2RENSLC6A5HRH1 | |
| SCHEMBL18857761 | 0.83 | SLC15A2 (0.58) | SLC15A2SLC6A5HRH1 | |
| SCHEMBL22722176 | 0.82 | REN (0.58) | SLC15A2RENSLC6A5HRH1 | |
| SCHEMBL27624890 | 0.82 | SLC15A2 (0.61) | SLC15A2REN | |
| SCHEMBL15186059 | 0.82 | SLC15A2 (0.55) | SLC15A2RENSLC6A5GRPR | |
| SCHEMBL15185951 | 0.82 | SLC15A2 (0.55) | SLC15A2RENSLC6A5GRPR | |
| SCHEMBL15186031 | 0.82 | SLC15A2 (0.55) | SLC15A2RENSLC6A5GRPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851367-B2 | Tissue-specific genome engineering using CRISPR-Cas9 | PFIZER INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20170137801-A1 | TISSUE-SPECIFIC GENOME ENGINEERING USING CRISPR-CAS9 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851367-B2 | Tissue-specific genome engineering using CRISPR-Cas9 | ASGR1, LDLR, HAVCR2 | SLC15A2 1937/4885REN 2795/4885SLC6A5 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.